Pharmalot… Pharmalittle… Good Morning
Make a commentBy Ed Silverman // February 2nd, 2011 // 8:05 am
Good morning, everyone. How are you today? Here on the Pharmalot corporate campus, the Iceman Cometh, but we are keeping warm with our traditional cup of stimulation. Please join us as we dig in, so to speak, for the usual routine of deadlines and the like. And as always, feel free to share interesting stories. By the way, we would like to note that we are co-sponsoring an upcoming conference on patient adherence. We hope you will join us. Meanwhile, here are a few tidbits to help you along. Have a great day…
Lilly & Bristol End Enrollment For Lung Cancer Trial Over Safety (Reuters)
Sanofi Fails To Block Generic Taxotere In Australia (Bloomberg News)
Glaxo Sells Quest Stake For $1.7 Billion (Reuters)
Anti-Counterfeit Rules Will Limit Access To Meds: Oxfam (The Guardian)
S&P Mulling Over Downgrade For Sanofi-Aventis (Associated Press)
EU Approves AstraZeneca Nasal Flu Vaccine For Kids (Reuters)
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
AstraZeneca, Australia, Bristol Myers Squibb, Counterfeit Medicines, Eli Lilly, Flu, Fluenz, Generics, GlaxoSmithKline, Oxfam, Patents, Quest Diagnostics, S&P, Sanofi Aventis, Standard & Poor's, Taxotere, Vaccines